2005
DOI: 10.1590/s1516-93322005000200004
|View full text |Cite
|
Sign up to set email alerts
|

Latenciação e formas avançadas de transporte de fármacos

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
23
0
18

Year Published

2010
2010
2023
2023

Publication Types

Select...
5
3
2

Relationship

1
9

Authors

Journals

citations
Cited by 29 publications
(41 citation statements)
references
References 75 publications
0
23
0
18
Order By: Relevance
“…1 Since then, prodrugs have been highly explored to overcome several biologic barriers in drug delivery such as absorption, distribution and enzymatic metabolism. 2 In drug development programs, difficulties such as low solubility, premature degradation, short half-life and other pharmacokinetic and pharmacodynamic parameters can also be tackled with a prodrug approach. 3 However, in order to become a prodrug candidate, a molecule must present some features such as biologic inactivity, absence of toxicity, simple synthetic route, a biolabile drug-carrier conjugate and ensure effective concentration of the drug in the target tissues.…”
Section: Introductionmentioning
confidence: 99%
“…1 Since then, prodrugs have been highly explored to overcome several biologic barriers in drug delivery such as absorption, distribution and enzymatic metabolism. 2 In drug development programs, difficulties such as low solubility, premature degradation, short half-life and other pharmacokinetic and pharmacodynamic parameters can also be tackled with a prodrug approach. 3 However, in order to become a prodrug candidate, a molecule must present some features such as biologic inactivity, absence of toxicity, simple synthetic route, a biolabile drug-carrier conjugate and ensure effective concentration of the drug in the target tissues.…”
Section: Introductionmentioning
confidence: 99%
“…Regarding prodrug design strategy, or latentiation method, the main purpose is to modify physicochemical properties of drugs to reduce undesirable pharmacokinetic features, but maintaining drug's intrinsic activity. Thus, the drugs' physicochemical properties can be adjusted through a proper choice of carrier groups in order to increase oral absorption, for example (11,12).…”
Section: Introductionmentioning
confidence: 99%
“…It is a temporarily inactive compound that, once inside the organism, needs to be metabolized to attain its active form (Bundgaard, 1985;Bundgaard, 1991;Chung et al, 2005;Liederer, Borchardt, 2006;Parise-Filho et al, 2007;Rautio et al, 2008;Silva et al, 2005;Stella, 2004;Wermuth, 2006).…”
Section: Introductionmentioning
confidence: 99%